-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Reported Final Results From Phase 2 Study Of Its Lead Oncology Drug, CM24, In Patients With Pancreatic Ductal Adenocarcinoma

Benzinga·12/02/2024 12:15:15
Listen to the news
  • Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints.
  • A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with median PFS improvement of 2.9 months and improvement in the treatment arm over the control in ORR of 50% vs. 0%.
  • Phase 2b clinical study is planned in multiple selected indications, potentially targeting patients based on biomarkers